May 12, 2026 07:30AM

May 12, 2026 07:30AM

Mar 9, 2026 05:16PM

Aug 8, 2024 05:51PM

Nov 29, 2023 07:30AM

Oct 19, 2023 07:30AM

Oct 19, 2023 07:30AM SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Apr 26, 2023 08:30AM

Apr 26, 2023 08:30AM

Apr 18, 2023 08:32AM

Apr 18, 2023 08:30AM

Apr 13, 2023 08:31AM

Apr 13, 2023 08:30AM

Jan 10, 2023 08:00AM SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

Nov 21, 2022 08:14AM

Aug 9, 2022 04:30PM

Mar 2, 2022 06:00AM

Mar 2, 2022 06:00AM

Mar 2, 2022 05:53AM

Mar 1, 2022 07:30PM

Jan 24, 2022 06:00AM SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19

Dec 16, 2021 06:01AM

Dec 16, 2021 06:00AM

Oct 25, 2021 07:39AM

322,656 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All